SCHEMBL6024686

SCHEMBL6024686

Cc1[nH]c(=O)cc(O)c1C=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.51
CYP3A4 P08684 2/20 0.41
MAPT P10636 1/20 0.41
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
HPGD P15428 2/20 0.38
GLA P06280 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.36
USP2 O75604 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.35
CA1 P00915 1/20 0.34
CYP1A2 P05177 2/20 0.34
UPP1 Q16831 1/20 0.34
SHMT2 P34897 1/20 0.34
HTT P42858 1/20 0.33
CYP2C19 P33261 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13607108 0.79 ERN1 (0.50) ERN1MAPTKDM4EALDH1A1GAA
SCHEMBL6247191 0.74 KDM4E (0.41) ERN1KDM4EALDH1A1GAAHPGD
SCHEMBL11439086 0.72 ERN1 (0.56) ERN1CYP3A4MAPTKDM4EALDH1A1
SCHEMBL3185655 0.69 ERN1 (0.52) ERN1CYP3A4MAPTKDM4EALDH1A1
SCHEMBL27980095 0.68 CYP3A4 (0.51) CYP3A4MAPTKDM4EALDH1A1GAA
SCHEMBL6024645 0.68 KDM4E (0.43) KDM4EALDH1A1SMN1; SMN2HSD17B10L3MBTL1
SCHEMBL2493416 0.67 SMN1; SMN2 (0.50) ERN1SMN1; SMN2
SCHEMBL8913451 0.67 ERN1 (0.43) ERN1CYP3A4MAPTKDM4EGAA
SCHEMBL9455125 0.67 GAA (0.38) ERN1MAPTKDM4EALDH1A1GAA
SCHEMBL16965192 0.67 UPP1 (0.58) MAPTKDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115608-B2 Pyridinone and pyridinethione derivatives having HIV inhibiting properties CENTRE NATIONAL DE LA RECHERCHE SCHENTIFIQUE (FR) 2006-10-03 US disclosed
EP-1318995-B1 PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES CENTRE NAT RECH SCIENT (FR) 2006-03-08 EP disclosed
US-20040229847-A1 Pyridinone and pyridinethione derivatives having hiv inhibiting properties CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2004-11-18 US disclosed
EP-1318995-A2 PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2003-06-18 EP disclosed
WO-2002024650-A2 PYRIDINONE AND PYRIDINETHIONE DERIVATIVES HAVING HIV INHIBITING PROPERTIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229847-A1 Pyridinone and pyridinethione derivatives having hiv inhibiting properties CYP2B6, CYP2S1, CYP2D6 ERN1 2090/4885CYP3A4 45/4885MAPT 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.